PITTSBURGH, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced that it has expanded the available applications for its ...
PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data ...
Stanford Medicine has developed a vision-language artificial intelligence (AI) model that can predict cancer outcomes, such as forecasting melanoma relapses and patient responses to immunotherapy.
Predictive Oncology, Inc. (NASDAQ:POAI) stock is trading higher on Tuesday after the company reported results from utilizing artificial intelligence (AI) for drug repurposing. The Details: Predictive ...
Forbes contributors publish independent expert analyses and insights. David Henkin helps organizations and individuals innovate and grow. Predictive analytics has evolved from a niche discipline into ...
Discordance Between the Initial Diagnosis of Sarcomas and Subsequent Histopathological Revision and Molecular Analyses in a Sarcoma Reference Center in Brazil In this prospective study of 170 patients ...
Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas Unanticipated health care resource utilization, in the form of ...
Zohar Bronfman is the cofounder and CEO of Pecan AI, a predictive analytics platform making advanced AI accessible to business teams. For decades, predictive analytics was a capability largely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results